(Q56550815)

5

object named as

Suryaprakash Sambhara

0 references

author name string

Mary Hoelscher

1

0 references

Shivaprakash Gangappa

2

0 references

Weimin Zhong

Expert Opinion on Drug Delivery

3

0 references

language of work or name

English

0 references

publication date

October 2008

0 references

published in

0 references

volume

5

0 references

issue

10

0 references

page(s)

1139-57

0 references

cites work

Mortality associated with influenza and respiratory syncytial virus in the United States

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Complications of viral influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Influenza vaccination in pregnancy: current evidence and selected national policies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Vaccination and perinatal infection prevention practices among obstetrician-gynecologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Influenza vaccination of recommended adult populations, U.S., 1989-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Probable person-to-person transmission of avian influenza A (H5N1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Three Indonesian clusters of H5N1 virus infection in 2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Detecting human-to-human transmission of avian influenza A (H5N1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

A review of avian influenza in different bird species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Epidemiology, Production Losses, and Control Measures Associated with an Outbreak of Avian Influenza Subtype H7N2 in Pennsylvania (1996–98)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Human infection with influenza H9N2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Safety and immunogenicity of trivalent inactivated influenza vaccine in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Severe pediatric influenza in California, 2003-2005: implications for immunization recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

A Toll-like receptor recognizes bacterial DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

New technology platforms in the development of vaccines for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Immunostimulating reconstituted influenza virosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Evidence for host-cell selection of influenza virus antigenic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Humoral and cell-mediated immunity to vero cell-derived influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Evaluation of a cold-recombinant influenza virus vaccine in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Sequence changes in the live attenuated, cold-adapted variants of influenza A/Leningrad/134/57 (H2N2) virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Live attenuated versus inactivated influenza vaccine in infants and young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Pandemic versus epidemic influenza mortality: a pattern of changing age distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Pandemic Threat Posed by Avian Influenza A Viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Trials of Influenza A/New Jersey/76 Virus Vaccine in Normal Children: An Overview of Age-Related Antigenicity and Reactogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Development and preclinical evaluation of an alphavirus replicon vaccine for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

MVA as a vector for vaccines against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

New hope for an AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Heterologous protection against influenza by injection of DNA encoding a viral protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Evaluating the vaccine potential of an influenza A viral hemagglutinin and matrix double insertion DNA plasmid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Immunogenicity of novel consensus-based DNA vaccines against avian influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Antibody response to the M2 protein of influenza A virus expressed in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

A universal influenza A vaccine based on the extracellular domain of the M2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Modified M2 proteins produce heterotypic immunity against influenza A virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Universal influenza A vaccine: optimization of M2-based constructs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Molecular mechanisms of endotoxin tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Antigens onto bare skin: a 'painless' paradigm shift in vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Transcutaneous immunization and immunostimulant strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Induction of protective immunity against lethal anthrax challenge with a patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Methods for conducting systematic reviews of targeted vaccination strategies for the guide to community preventive services

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139

Interventions to improve influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among high-risk adults: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.5.10.1139